EDINBURGH, Scotland--(BUSINESS WIRE)-- <\/p>\n
Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announcethat it has completed a financing round of 5.2M. Participants included existing investors Calculus Capital, the Scottish Investment Bank, the investment arm of Scottish Enterprise and private shareholders. <\/p>\n
Synpromics has grown rapidly over the past two years as it expanded its portfolio of international customers. These include leading gene therapy companies and multinational technology corporations, most recently GE Healthcare. <\/p>\n
The majority of the new investment will be used to further develop and exemplify Synpromics proprietary PromPT synthetic promoter design platform. PromPT enables the design of unique synthetic promoters which give precise control of gene function in many areas of gene medicine including gene therapy, cell therapy and gene editing. The Company is also preparing to move into a larger, new purpose built, facility. <\/p>\n
David Venables, CEO of Synpromics, commented Since our last fundraising round 18 months ago the business has grown rapidly as weve signed more commercial partnerships with companies in the US and Europe. We see an exciting opportunity to fund further rapid expansion of our business, supported by our innovative science and novel capabilities. <\/p>\n
Alexandra Lindsay, Investment Director at Calculus Capital, added We have been delighted with the progress which Synpromics has made since we made our first investment some 18 months ago. They have a very strong team and the technology has been clearly validated through partnerships with some of the worlds leading gene medicine companies. <\/p>\n
Kerry Sharp, Head of the Scottish Investment Bank, said Having supported Synpromics from an early stage it is great to see the progress that has been achieved to develop and grow the business in the highly dynamic synthetic biology industry.We look forward to continuing to work with the company, both from an investment perspective and through our account management support, to deliver its long term growth ambition. <\/p>\n
-Ends- <\/p>\n
Notes to Editors <\/p>\n
About Synpromics <\/p>\n
Synpromics is a private company focused on commercialising its proprietary technology in the emerging field of synthetic biology by developing customised synthetic promoters. The company has partnership deals with a number of gene therapy companies including AGTC, Adverum, and uniQure, and bioprocessing companies such as GE Healthcare and Sartorius-Stedim Celca. <\/p>\n
Synpromics technology gives biological researchers, developers and manufacturers unprecedented control of gene expression through the ability to create a comprehensive portfolio of man-made DNA regulatory sequences. <\/p>\n
Synthetic promoters are DNA sequences that do not exist in nature and are designed to regulate the activity of genes, controlling a genes ability to produce its own uniquely encoded protein. Currently, the biotech industry largely relies on naturally occurring promoters to drive protein production. However, natural promoters have evolved for biological functions within the context of the organism in question, and as such they were not purpose-designed for industrial or therapeutic applications. The technology developed by Synpromics allows for the design of synthetic promoters that are optimally tailored to drive gene expression at the desired level and specificity. The technology platform facilitates the creation of a large collection of distinct and relevant synthetic promoters for a diverse array of applications <\/p>\n
For more information see http:\/\/www.synpromics.com<\/a> <\/p>\n About Calculus Capital <\/p>\n Calculus Capital is a specialist in creating and managing private equity funds for individuals. A pioneer in the Enterprise Investment Scheme (EIS) space, Calculus launched the UKs first HMRC-approved EIS fund in 1999 and has gone on to launch 16 further funds and four VCT offers. Calculus seeks capital appreciation from dynamic, established, private UK companies across a multitude of sectors. Calculus prefers to invest 2m-5m per company.As at January 2017 it had over 130m of funds under management. <\/p>\n Calculus Capitals experienced investment team, diligent investment process and hands on approach have resulted in an impressive track record of investment success. Calculus has won multiple awards including Best EIS Fund Manager at the Growth Investor Awards 2016 and the EIS Associations Fund Manager of the Year Award in 2016, 2015, 2014, 2011 and 2009. <\/p>\n Read More <\/p>\n <\/p>\n Read the original post: EDINBURGH, Scotland--(BUSINESS WIRE)-- Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announcethat it has completed a financing round of 5.2M. Participants included existing investors Calculus Capital, the Scottish Investment Bank, the investment arm of Scottish Enterprise and private shareholders. Synpromics has grown rapidly over the past two years as it expanded its portfolio of international customers. Continue reading
\nSynpromics Raises 5.2M of New Investment - Yahoo Finance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"